Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bisacodyl laxative six-month carcinogenicity study in mice planned by NDMA.

This article was originally published in The Tan Sheet

Executive Summary

BISACODYL SIX-MONTH CARCINOGENICITY STUDY IN MICE to be conducted by the Nonprescription Drug Manufacturers Association Bisacodyl Task Group, NDMA says in a Sept. 29 letter to FDA. Intended to verify the safety of the OTC stimulant laxative ingredient, the study is being organized in response to FDA's request for additional data to substantiate bisacodyl's Category I (safe and effective) status. FDA's Carcinogenicity Assessment Committee recommended further study of bisacodyl at its April 30 meeting on phenolphthalein ("The Tan Sheet" May 5, p. 6). Although the meeting was held to consider the National Toxicology Program's carcinogenicity data for phenolphthalein, CAC suggested genotoxicity testing for several other stimulant laxative ingredients, including bisacodyl, aloe, senna and cascara sagrada.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts